New drug tracking study offers clues for future cancer treatments
NCT ID NCT06308263
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 26 times
Summary
This study looked at how the experimental drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received the drug by mouth and by IV with a tiny radioactive marker to track it. The main goal was to understand the drug's path in the body, not to treat the cancer, though some could continue the drug if it helped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmaceutical Research Associates Magyarország Kutatás - Fejlesztési Kft., Klinikai Farmakológiai Vizsgálóhely
Budapest, Hungary
Conditions
Explore the condition pages connected to this study.